• Publications
  • Influence
Comparing Mycophenolate Mofetil Regimens for de Novo Renal Transplant Recipients: The Fixed-Dose Concentration-Controlled Trial
Background. Fixed-dose mycophenolate mofetil (MMF) reduces the incidence of acute rejection after solid organ transplantation. The Fixed-Dose Concentration Controlled trial assessed the feasibilityExpand
One‐Year Results with Extended‐Release Tacrolimus/MMF, Tacrolimus/MMF and Cyclosporine/MMF in De Novo Kidney Transplant Recipients
Once‐daily tacrolimus extended‐release formulation (Prograf XL, formerly referred to as MR or MR4) was compared with the twice‐a‐day tacrolimus formulation (TAC) and cyclosporine microemulsion (CsA),Expand
Novel Once‐Daily Extended‐Release Tacrolimus (LCPT) Versus Twice‐Daily Tacrolimus in De Novo Kidney Transplants: One‐Year Results of Phase III, Double‐Blind, Randomized Trial
This Phase III randomized trial examined efficacy and safety of a novel once‐daily extended‐release tacrolimus formulation (LCP‐Tacro [LCPT]) versus twice‐daily tacrolimus in de novo kidneyExpand
Tacrolimus Once-Daily Formulation in the Prophylaxis of Transplant Rejection in Renal or Liver Allograft Recipients
tacrolimus. Interestingly, (unlike standard Tacrolimus Once-Daily tacrolimus) tacrolimus OD did not show a statistiFormulation in the Prophylaxis of cally significant reduction in the incidence ofExpand
Randomized Trial of Everolimus-Facilitated Calcineurin Inhibitor Minimization Over 24 Months in Renal Transplantation
Background Strategies allowing calcineurin inhibitor minimization while maintaining efficacy may improve renal transplant outcomes. Methods A2309 was a 24-month, phase IIIb, open-label trial of 833Expand
Pharmacokinetics of an Everolimus‐Cyclosporine Immunosuppressive Regimen Over the First 6 Months After Kidney Transplantation
The pharmacokinetics of everolimus were characterized over the first 6 months post transplant in 731 patients receiving either 0.75 or 1.5 mg bid everolimus in addition to cyclosporine andExpand
Mycophenolate Mofetil Substitution for Cyclosporine A in Renal Transplant Recipients with Chronic Progressive Allograft Dysfunction: The “Creeping Creatinine” Study1
Background. This study determined whether cyclosporine A (CsA)-treated renal allograft recipients with deteriorating renal function (“creeping creatinine”) secondary to chronic allograft nephropathyExpand
Evaluation of the Effect of Tofacitinib Exposure on Outcomes in Kidney Transplant Patients
Tofacitinib fixed‐dose regimens attained better kidney function and comparable efficacy to cyclosporine (CsA) in kidney transplant patients, albeit with increased risks of certain adverse events.Expand
Planned Randomized Conversion From Tacrolimus to Sirolimus‐Based Immunosuppressive Regimen in De Novo Kidney Transplant Recipients
Planned conversion from tacrolimus to sirolimus was evaluated in de novo kidney transplant recipients. In this multicenter, randomized, open‐label study, 297 patients were initially treated withExpand
Gingival overgrowth among patients medicated with cyclosporin A and tacrolimus undergoing renal transplantation: a prospective study.
BACKGROUND The aim of this study is to make a longitudinal evaluation of the incidence and severity of gingival overgrowth (GO) induced by immunosuppressive agents, such as tacrolimus (Tcr) andExpand